Paris-based TISSIUM raises €50 million in Series D round to launch its first tissue reconstruction products
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners. This latest funding round…
This content is for members only. Visit the site and log in/register to read.
The post Paris-based TISSIUM raises €50 million in Series D round to launch its first tissue reconstruction products appeared first on EU-Startups.